News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

SCHOTT Corporation Marks Growth Of Its Global Syringe Business With Renewed Commitment To Innovation


11/13/2013 2:09:53 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

San Antonio, TX -- The international technology group SCHOTT announced the rebranding of its glass syringes, now known as syriQTM (previously forma 3s). The new name comes on the heels of growth in the field of prefillable syringes, and represents SCHOTT’s renewed commitment to delivering high quality pharmaceutical packaging. SCHOTT will display its syriQTM product line at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in San Antonio, Texas on November 11 to 14, 2013 at booth #4209. Picture No. 216990: SCHOTT emphasizes the growth prospects of its global syringe business. The company presented its new brand appearance at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in San Antonio, Texas.

“It has always been our strategy to engage in open dialogues with our customers,” said Dr. Jürgen Sackhoff, Executive Vice President of SCHOTT Pharmaceutical Systems. “Integrating with their processes enables us to discover the best solutions. We’ll continue this collaboration under the syriQ brand with a new vision for further innovations, especially in the area of prefillable glass syringes.”

SCHOTT has been manufacturing glass and polymer syringes in Europe and the U.S. for more than 12 years and recently doubled its production capacities for TopPac polymer syringes. The production facility in St. Gallen, Switzerland is a center of excellence, harboring a top-notch on site R&D team and maintaining a large annual production capacity to ensure security of supply. The factory also houses the infrastructure needed for further expansion.

To offer pharmaceutical companies a broad range of solutions, SCHOTT holds a complete portfolio of both glass and polymer syringes. In the field of glass syringes, the offerings range from 0.5 to 3 milliliter (ml) products, suitable for a variety of applications, such as heparin, vaccines, biotechnology, and special applications. With regard to polymer syringes, the company has completed its portfolio of large volume syringes for intensive care, which now includes the entire range of 10 ml, 20 ml, and 50 ml formats.

The photos appearing in this press release can be downloaded in high resolution from: https://www.schott-pictures.net/presskit/217220.syriq

About SCHOTT

SCHOTT is an international technology group with more than 125 years of experience in the areas of specialty glass and materials and advanced technologies. SCHOTT ranks number one in the world with many of its products. Its core markets are the household appliance, pharmaceuticals, electronics, optics, transportation and architecture industries. The company is strongly committed to contributing to its customers’ success and making SCHOTT an important part of people’s lives with high-quality products and intelligent solutions. SCHOTT is committed to managing its business in a sustainable manner and supporting its employees, society and the environment. The SCHOTT Group maintains close proximity to its customers with manufacturing and sales units in all major markets. Its workforce of around 16,000 employees generated worldwide sales of $2.6 billion (approximately 2.0 billion euros) for the 2011/2012 fiscal year.

Press contact:

Rina Della Vecchia

SCHOTT North America, Inc.

Phone: 914-831-2286

Fax: 914-831-2201

rina.dellavecchia@us.schott.com

Mike Lizun

Gregory FCA on behalf of SCHOTT

Office: 610-642-1435

mike@gregoryfca.com

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES